Scinovex
reviewTop 1% cited

Risk of first‐generation H<sub>1</sub>‐antihistamines: a GA<sup>2</sup>LEN position paper

Allergy · 2010 · Vol. 65(4) · pp. 459–466
Martin K. ChurchMarcus MaurerF. Estelle R. SimonsCarsten Bindslev‐JensenPaul Van CauwenbergeJean BousquetStephen T. HolgateTorsten Zuberbier

Abstract

This review raises the issue of better consumer protection by recommending that older first-generation H(1)-antihistamines should no longer be available over-the-counter as prescription- free drugs for self-medication of allergic and other diseases now that newer second- generation nonsedating H(1)-antihistamines with superior risk/benefit ratios are widely available at competitive prices.

Asthma and respiratory diseasesAllergic Rhinitis and SensitizationFood Allergy and Anaphylaxis ResearchMedicineMedical prescriptionPublic healthAsthmaOver-the-counterMedical emergencyAuditFamily medicinePediatricsPsychiatry

MeSH terms

BrainCognitionNonprescription DrugsHistamine H1 AntagonistsHumansHypersensitivityUnited StatesDrug Approval
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.